AtriCure (ATRC) investor plans to sell 6,000 shares in Rule 144 filing

Rhea-AI Filing Summary

Vinayak Doraiswamy, a shareholder of AtriCure, Inc. (symbol ATRC), has filed to sell 6,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The filing lists an aggregate market value of $233,278.80 for these shares, with AtriCure common shares outstanding reported at 50,866,294. The proposed sale date is July 28, 2026.

The shares to be sold relate to performance share awards dated March 1, 2023 (2,596 shares) and March 1, 2025 (3,404 shares). In the past three months, a prior sale of 5,000 common shares on May 15, 2026 for proceeds of $140,674.00 is also reported.

Key Figures

Shares to be sold: 6,000 shares Aggregate market value of planned sale: $233,278.80 Shares outstanding: 50,866,294 shares +5 more

8 metrics

Shares to be sold 6,000 shares Common stock covered by the planned Rule 144 sale

Aggregate market value of planned sale $233,278.80 Value attributed to the 6,000 common shares to be sold

Shares outstanding 50,866,294 shares AtriCure common shares reported outstanding

Proposed sale date 07/28/2026 Planned date for the 6,000-share sale

Prior 3-month sale shares 5,000 shares Common shares sold on 05/15/2026

Proceeds from prior sale $140,674.00 Amount received for 5,000 shares sold on 05/15/2026

Performance shares 2023 award 2,596 shares Common shares from 03/01/2023 performance share award

Performance shares 2025 award 3,404 shares Common shares from 03/01/2025 performance share award

Key Terms

Form 144, Performance Shares, aggregate market value, Securities Sold During The Past 3 Months

4 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Performance Shares financial

"Common | 03/01/2023 | Performance Shares | Issuer"

Performance shares are a type of company stock given to executives or employees that only become theirs if the company meets specific goals, like hitting certain profits or growth targets. They motivate leaders to work toward the company’s success, because their additional shares depend on achieving these results.

aggregate market value financial

"6000 | 233278.80 | 50866294 | 07/28/2026"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Securities Sold During The Past 3 Months regulatory

"144: Securities Sold During The Past 3 Months"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/28/2026 - 04:04 PM Accepted by SEC EDGAR 07/28/2026 - 04:03 PM Learn about SEC filing dates

FAQ

What amount of ATRC common stock is Vinayak Doraiswamy planning to sell?

Vinayak Doraiswamy plans to sell 6,000 shares of AtriCure (ATRC) common stock. The filing reports an aggregate market value of $233,278.80 for these shares and identifies Morgan Stanley Smith Barney LLC as the brokerage handling the transaction.

When is the planned sale date for the ATRC shares in this Form 144 filing?

The planned sale date for the AtriCure (ATRC) common shares is July 28, 2026. This date is disclosed as the proposed date of sale for the 6,000 shares covered under the Form 144 notice.

How many ATRC shares were sold by Vinayak Doraiswamy in the last three months?

In the last three months, Vinayak Doraiswamy reported selling 5,000 shares of AtriCure (ATRC) common stock. The sale occurred on May 15, 2026 and generated reported proceeds of $140,674.00.

What performance share awards underpin the ATRC shares to be sold?

The planned sale of AtriCure (ATRC) shares relates to performance shares from awards dated March 1, 2023 and March 1, 2025. These correspond to 2,596 and 3,404 shares of common stock, respectively, totaling 6,000 shares.

How many ATRC common shares are reported outstanding in this filing?

The filing reports that AtriCure (ATRC) has 50,866,294 common shares outstanding. This figure is presented as a contextual share count and not as the number of shares being sold under this Form 144 notice.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	6000	233278.80	50866294	07/28/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/01/2023	Performance Shares	Issuer			2596	03/01/2023	Not Applicable
Common	03/01/2025	Performance Shares	Issuer			3404	03/01/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
VINAYAK DORAISWAMY 7555 Innovation Way Mason OH 45040	Common	05/15/2026	5000	140674.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)